Treatment of antipsychotic associated obesity with a GLP-1 Analogue: the TAO study Behandling af antipsykotika-associeret fedme med en GLP-1 analog: TAO studiet

Trial Profile

Treatment of antipsychotic associated obesity with a GLP-1 Analogue: the TAO study Behandling af antipsykotika-associeret fedme med en GLP-1 analog: TAO studiet

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2013

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms TAO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Dec 2013 Last checked against ClinicalTrials.gov record.
    • 15 Feb 2013 Planned End Date (Jul 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top